GlaxoSmithKline Pharmaceuticals' record is clean on its face: six years of unqualified audit opinions, no fraud reported, and a subsidiary that turned from a loss-maker into a ₹24 crore profit centre. Three things deserve attention: a ₹247 crore legacy pricing provision sits alongside a fresh wave of GST demands across multiple states, promoter voting power leaves public shareholders with no practical say on board appointments, and a one-time impairment of ₹637 crore on Ranitidine assets was taken in FY20 with no repeats.
Key findings
- A legacy pricing provision of ₹247 crore sits alongside fresh GST demands across states
Major- The Supreme Court upheld a ₹71.79 crore demand on Betamethasone bulk drugs on 31 March 2011, and the company deposited the full amount. The Government then claimed ₹247.44 crore in interest on 10 October 2011; the company provided the full sum and deposited ₹136.82 crore in three court-directed instalments. Since FY2024, fresh demands have emerged from Karnataka VAT (₹53.25 crore), Mumbai service tax (₹21.63 crore), Karnataka GST (₹8.57 crore), Madhya Pradesh GST (₹3.79 crore), and the National Pharmaceutical Pricing Authority (₹3.54 crore). - Promoter holds 75% and votes as a bloc, while public institutions dissent on directors
Minor- Glaxo Group and three fellow promoter entities hold 75.00% of paid-up capital and cast 127,054,524 shares in favour of every director resolution across all AGMs and postal ballots from FY21 to FY26. Public institutional shareholders voted 35.13% against the continuation of Ms. R. S. Karnad as Non-Executive Director on 28 June 2024, and 15.20% against the re-appointment of Dr. Sunita Maheshwari as Independent Director on 27 June 2025. - Revenue recognition is a recurring audit focus, and doubtful debt provisions spiked in FY25
Minor- Information Technology (IT) systems which impact financial reporting is a Key Audit Matter in the standalone and consolidated auditor reports for FY24 and FY25. The net provision for doubtful debts jumped to ₹2.38 crore in FY25 from ₹58.68 lakhs in FY24, following a net utilisation of ₹7.36 crore in FY23. No external customer exceeded 10% of total revenue in any year from FY22 through FY25. - Audit opinions stayed clean, and a backup compliance gap was resolved in FY26
Minor- The statutory auditor issued unqualified opinions on standalone and consolidated financial statements for every year from FY21 through FY26. A Section 143(3) exception for not maintaining daily backup of electronic books on a server physically located in India applied for FY2022-23, FY2023-24, and the period April 1, 2024 to November 28, 2024 in FY2024-25. The gap was resolved in FY26: the auditor confirmed the audit trail operated throughout the year with no tampering. - A one-time impairment of ₹637 crore on Ranitidine assets was taken in FY20, with no repeats
Clean- The company recognised a ₹637.43 crore impairment loss in FY20 on manufacturing assets tied to Ranitidine and Zinetac following the global voluntary recall. The post-impairment carrying value of ₹436.96 crore was supported by an independent valuer's estimate of ₹442.36 crore using Level 3 inputs. No impairment charges were reported in the annual reports for FY23, FY24, FY25, or FY26. - The sole subsidiary turned from a ₹17 crore loss in FY20 to a ₹24 crore profit in FY26
Clean- Biddle Sawyer Limited, held 100% throughout, reported nil revenue and a net loss of ₹16.91 crore in FY20 with negative retained earnings of ₹4.10 crore. By FY26, turnover reached ₹51.45 crore, profit after tax stood at ₹24.16 crore, and reserves and surplus had climbed to ₹49.78 crore. The group has no associates, joint ventures, or off-balance-sheet vehicles in any year.
What to watch
- Income Tax demands. Disputed demands of ₹1,140.00 crore remain pending before CIT(A) and ITAT as of the FY26 audit report dated 13 May 2026.
- Vemgal facility. The company stated in FY20 it was exploring future options including a potential sale; no subsequent update appears in filings through FY26.
- FY26 final dividend. Payment of ₹57 per share is subject to shareholder approval at the AGM noticed on 5 June 2026.
Bottom line: This is a disclosed and audited record with a clean audit trail and a subsidiary turnaround that is visible in the reported numbers. The risk sits in two places: the litigation docket, where a ₹247 crore legacy provision is now joined by fresh multi-state GST demands, and the governance structure, where 75% promoter control makes public shareholder dissent symbolic. Watch the tax hearings and the next AGM vote.